“Latest Stem Cells News”

Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori’s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function

Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company’s European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College of Cardiology. The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company’s proprietary Celution® System for the treatment of patients suffering from acute myocardial infarction.

In the APOLLO trial all patients were treated with standard-of-care and subsequently underwent an abdominal liposuction. Each patient’s adipose tissue was processed by the Celution® System where ADRCs were extracted, washed and concentrated into a syringe of clinical grade cells. Within 36 hours of the myocardial infarction and no longer than 24 hours after undergoing percutaneous coronary intervention, patients received an injection of either 20 million ADRCs (n=10) or a placebo (n=4).

Incoming search terms:

Scientists have taken the first steps toward producing the “heart patch,” a design for a medical implement used to repair damage from heart disease, a new study suggests.

Last week, researchers from Duke University presented the results of a study which, using mouse embryonic stem cells, examined the way these cells develop into heart muscle, HealthDay News reports (…)

from http://www.privatemdlabs.com/news/Heart_Health_and_Cholesterol/Mouse-stem-cell-study-examines-heart-repair$19405309.php

Incoming search terms:

Not all stem cells are ‘good’ at aiding the heart in repairing itself after a heart attack. Apparently, ‘baby cells’ present in human fat are the best equipped to perform this task and could be used in human testing by the end of 2009. “ We have seen that a simple stem cell transplant into a heart after a heart-attack is not sufficient. There are different types of stem cells that are better adapted to aiding the heart in the healing process. Instead of hematopoietic stem cells used in initial studies, mesenchymal stem cells are now being used.

Incoming search terms:

A team of researchers from UCL has won a £500,000 grant to develop a synthetic artery that mimics a natural artery – and could revolutionise the treatment of coronary heart disease.

Professor Alexander Seifalian (UCL Surgery and Interventional Science) and Professor George Hamilton (UCL Surgery and Interventional Science & Royal Free Hospital) and their team will use the Wellcome Trust grant to take their work from the laboratory to a pre-clinical trial.

The team has been developing a new nanomaterial with mechanical properties similar to that of human arteries.

The nanomaterial’s inner surface has been modified to attract stem cells from blood circulating inside the body.

It converts these primary cells to endothelial cells, a type of cell that covers the interior of the natural blood vessel and protects it from blockage.

The breakthrough offers hope for sufferers of heart disease who are unable to donate suitable substitute blood vessels for bypass surgery.

Professors Seifalian and Hamilton, experts in nanotechnology, regenerative medicine and vascular surgery, explained: “Coronary heart disease is a condition where one or more blood vessels of the heart become narrowed or blocked. This causes the heart muscle to be starved of oxygen causing damage often leading to a heart attack and muscle death. This interferes with the heart’s ability to pump blood around the body, leading to infirmity and possibly death.

“The current treatment of the disease is to create a new route for blood to circulate, most often by balloon dilatation and stent (stent angioplasty). In many patients however this intervention cannot be performed and in this situation an operation called bypass surgery is needed which can either use substitute blood vessels from another part of the patient or made from a plastic material.

read more: http://www.ucl.ac.uk/news/news-articles/0908/09081101

Incoming search terms: